Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILB-3101 phase I/II dose-escalation and expansion study in advanced solid tumors
CTR20243083Phase 2Active
- Sponsor
- Innolake Biopharm
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ILB-3101 in Nonhematologic neoplasms, sponsored by Innolake Biopharm. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicity incidence and 2 more. Started Nov 2024; status: active.
02
Drugs
ILB-3101
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20243083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243083.